Osteoprotegerin and TRAIL in acute onset of atrial fibrillation by Rewiuk, Krzysztof & Grodzicki, Tomasz
Research Article
Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation
Krzysztof Rewiuk and Tomasz Grodzicki
Chair of Internal Medicine and Gerontology, Jagiellonian University Medical College, Ulica S´niadeckich 10, 31-531 Krako´w, Poland
Correspondence should be addressed to Krzysztof Rewiuk; krewiuk@su.krakow.pl
Received 14 April 2015; Revised 14 June 2015; Accepted 22 June 2015
Academic Editor: Tatjana Potpara
Copyright © 2015 K. Rewiuk and T. Grodzicki. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background.There is a growing amount of evidence that inflammatory processes are involved in the development of atrial fibrillation
(AF) and its complications. We decided to investigate the behavior of osteoprotegerin (OPG) and TNF-related apoptosis inducing
ligand (TRAIL) in terms of acute onset of AF.Methods and Results. We included 60 patients with acute onset of AF, candidates for
pharmacological cardioversion.Thepresence of cardiovascular comorbidities was connectedwith higher concentration ofOPGand
lower level of TRAIL right from the first hours of AF paroxysm.The initial TRAIL level correlated also positively with left ventricle
ejection fraction and negatively with left atrium diameter.We found subsequent increase of OPG in subgroups selected on the basis
of CHA
2
DS
2
-VASc scoring. Although basal concentrations of studied markers did not allow prediction of the restoration of sinus
rhythm, we observed important increase of TRAIL concentration in subgroup with sinus rhythmmaintenance (94.11± 29.46 versus
111.39 ± 30.23 pg/mL; 𝑝 = 0.002). Conclusions. OPG and TRAIL are associated with the underlying cardiovascular damage in AF,
but their balance is modulated by the fact of sinus rhythm restoration. Determining the suitability of OPG and TRAIL as predictive
markers in AF requires further prospective studies.
1. Introduction
Atrial fibrillation (AF) is the most common clinically signifi-
cant arrhythmia, and its incidence is still increasing due to the
prolongation of life of the general population and improve-
ment of the prognosis of patients with structural heart disease
predisposing to the rhythm disturbances [1]. Key research
from the turn of the centuries has confirmed that the essential
for the prognosis of patients is not so much arrhythmia
itself, but rather the associated risk of thromboembolic events
[2]. As this risk is generally independent of the pattern of
AF (paroxysmal or persistent) it seems to be a legitimate
claim that reasons of hypercoagulability in AF are not only
hemodynamic.Themost widely accepted theory refers to the
concept of Virchow’s triad of the role of serum factors and
endothelial function in the pathogenesis of AF [3]. Among
hundreds of analyzed molecules important significance is
also attributed to the markers of inflammation, including
superfamily of tumor necrosis factor (TNF) receptors.
One of the representatives of this group is osteoprotegerin
(OPG), protein playing the key role in the bone homeostasis
and binding bone metabolism with calcification processes of
the cardiovascular system [4]. Although OPG is not regarded
as a classic marker of endothelial function it should be noted
that the substance is stored in the Weibel-Palade bodies and
secreted simultaneously with vonWillebrand factor [5]. OPG
in vitro has protective effects on endothelium: it prevents
apoptosis of endothelial cells, induces their growth and
differentiation, and inhibits further calcification of media [6–
8]. Paradoxically, in clinical studies higher concentrations of
OPG in serum correlate with the endothelial dysfunction,
degree of vessel wall calcification, presence of cardiovascular
risk factors, and cardiovascular mortality [8–14]. This phe-
nomenon might be explained by a compensatory increase in
the concentration of OPG in response to the endothelium-
damaging factors.
Influence of the OPG on the endothelium may be mod-
ulated by interaction with TNF-related apoptosis inducing
ligand (TRAIL). TRAIL originally identified as a molecule
participating in the process of cytotoxicity with respect to
tumor cells has been also proved to be involved in a variety
of other mechanisms engaged in activation, migration, and
proliferation of various cell types. TRAIL’s various interfer-
ence with the particular types of cells is due to its ability
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to bind to the five different types of receptors (including
OPG) [4]. There are observations which indicate a protective
effect of the soluble form of TRAIL in the cardiovascular
diseases, which could be explained by the resistance of
the endothelium against induced apoptosis [7, 15, 16]. It
seems that the paradoxical beneficial effect of TRAIL on
the endothelium may correspond to the interaction between
OPG and TRAIL.
Although there are several pieces of data on the activity
of OPG and TRAIL in permanent AF in patients undergoing
surgery for mitral valve as well as patients treated with
electrical cardioversion [17–20], to our best knowledge this
issue has not been studied in subjects with acute onset of AF
who underwent pharmacological cardioversion. Therefore,
we have undertaken to measure the concentration of both
mentioned above markers in plasma of patients with symp-
tomatic AF lasting less than 48 hours and assess its clinical,
echocardiographic, and biochemical correlations in this acute
state, as well as prognostic significance regarding the presence
of sinus rhythm 7–10 days after attempt of pharmacological
cardioversion.What ismore we explore the dynamics of OPG
and TRAIL concentration in the case of sinus rhythm return
or AF persistence.
2. Materials and Methods
2.1. Patients. The study has enrolled consecutive adult
patients of the Clinical Department of Internal Diseases and
Geriatrics, University Hospital in Cracow, who meet the
following criteria: onset of AF lasting less than 48 hours
with symptoms that can be attributed unambiguously to
the arrhythmia, qualification for pharmacological cardiover-
sion (hemodynamic stability, absence of coronary pain, the
chances of maintaining sinus rhythm in the opinion of the
treating physician, lack of contraindications to propafenone
or amiodarone, and the patient’s consent), and informed
consent to participate in the study. Exclusion criteria were as
follows: hemodynamic instability, acute coronary syndrome,
the presence of other indications for electrical cardioversion,
acute or chronic inflammatory disease, and cancer.
All study patients were examined twice: during the onset
of AF between 12 and 48 hours of the arrhythmia and 7–10
days after the first test.
The treatments used in the meantime including the type
and dose of antiarrhythmic drugs were left at the discretion
of leading physicians. The participants were divided into two
groups based on the maintenance of sinus rhythm or AF
persistence during follow-up (SR group: sinus rhythm, AF
group: permanent atrial fibrillation).
The fact of atrial fibrillation was confirmed by standard
12-lead ECG.The time of occurrence of arrhythmiawas based
on the interview with the patient, taking into considera-
tion symptoms, which can be probably associated with the
arrhythmia (palpitations, anxiety in the precordial area, etc.).
During the control visit the presence of AF or sinus
rhythm was verified by standard 12-lead ECG. The obtained
data was supplemented by information on the treatment used
in the meantime.
2.2. Blood Sample Collection. Blood samples were drawn
from antecubital veins into EDTA tubes from all patients
in the fasted state. Lipid profile and high sensitive CRP
were measured using well-established methods routinely
used in clinical practice. For the osteoprotegerin and TRAIL
measurement samples taken were centrifuged for 15 minutes
at 3500 rpm. The resulting supernatant was frozen at −70∘C
until analysis. After collection a set of samples have been
thawed in the Department of Diagnostic SU in Krakow and
used to determine the concentration of both markers.
2.3. Enzyme Immunoassays. Plasma humans concentration
of osteoprotegerin (BioVendor, Minneapolis, MN, USA)
and TRAIL (R&D Systems Research Diagnostic, Brno,
CzechRepublic)weremeasured using commercially available
ELISA kit. Each measurement was performed according to
the manufacturer’s instructions.
2.4. Echocardiography. All patients underwent two-dimen-
sional transthoracic Doppler echocardiography using a GE
Vivid 3 Ultrasound system (General Electric Company)
according to the standards of the Polish Cardiac Society. The
size of the left atriumwas assessed in the parasternal long axis
view. For the evaluation of left ventricular ejection fraction
(EF) Simpson method was used.
2.5. Statistical Analysis. All statistical analyses of the results
were performed with Statistica 10 (StatSoft Inc.) measure-
ment. Data are expressed as mean ± SD for normal distri-
bution or medians and ranges for distribution differ from
the normal after verification of distribution by Shapiro-
Wilk test. For further analyses concentration of OPG was
logarithmized. Comparisons of the two independent groups
were performed using Student’s t-test or nonparametric
Mann-Whitney test, according to the distribution of vari-
ables. To assess the differences between pairs of biochemical
measurements (visit I versus visit II) t-test for dependent
values was used, separately in patients with restored sinus
rhythm and atrial fibrillation.The linear correlations between
OPG, TRAIL, and continuous variables were analyzed, using
Pearson linear correlation coefficient. A 𝑝 value < 0.05 was
considered significant.
3. Results
3.1. Basic Clinical Characteristics of Patients. The study group
consisted of 60 patients aged from 26 to 88 years, and
mean age was 65.15 ± 10.76 years. Among the respondents,
there were 27 women (45% of patients). Average body
mass index was 27.27 ± 4.60 kg/m2. Among the typical
risk factors for atrial fibrillation 50 (83.33%) patients pre-
sented with hypertension, 17 (28.33%) with heart failure, 34
(56.67%) with coronary artery disease (including previous
myocardial infarction in 8 patients), and 15 with (25%)
significantmitral valve disease. Only 4 participants presented
no risk factors for atrial fibrillation and were considered as
patients with lone form of arrhythmia. The oral prophylaxis
with acenocoumarol was realized in 36 (60%) patients.
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Table 1: Characteristics of study group with the division into AF persistent and SR restored subgroups.
SR AF 𝑝
Age (years), mean ± SD 63.38 ± 11.74 68.43 ± 7.90 0.08
Male, 𝑛 (%) 22 (56.41%) 11 (52.38%) 0.77
BMI (kg/m2), mean ± SD 26.22 ± 4.18 29.38 ± 4.78 <0.05
Heart rate (bpm), mean ± SD 99.46 ± 25.71 103.86 ± 25.00 0.53
RRsyst (mmHg), mean ± SD 127.44 ± 15.76 132.14 ± 18.27 0.30
RRdiast (mmHg), mean ± SD 82.82 ± 11.05 83.57 ± 10.14 0.80
LA (mm), mean ± SD 43.03 ± 6.87 51.14 ± 7.11 <0.001
Ao (mm), mean ± SD 31.61 ± 4.49 33.86 ± 4.59 0.08
ACS (mm), mean ± SD 19.60 ± 3.21 19.67 ± 2.35 0.94
LVESd (mm), Me [Q1; Q3] 32.5 [30; 36] 38 [32; 44] 0.01
LVEDd (mm), Me [Q1; Q3] 48 [46; 55] 54 [50; 56] 0.03
EF (%), Me [Q1; Q3] 60 [56; 65] 51 [35; 61] 0.03
IVSs (mm), mean ± SD 15.26 ± 2.34 14.81 ± 2.89 0.53
IVSd (mm), mean ± SD 11.17 ± 1.62 11.48 ± 2.46 0.58
PWs (mm), Me [Q1; Q3] 16 [14; 17] 16 [14; 18] 0.75
PWd (mm), Me [Q1; Q3] 11 [10; 12] 11 [10; 12] 0.66
RV (mm), Me [Q1; Q3] 24 [22.5; 25] 25 [24; 26] 0.25
TP (mm), Me [Q1; Q3] 24 [22; 25.5] 24 [22; 26] 0.45
Cholesterol tot. (mmol/L), mean ± SD 5.12 ± 1.32 4.22 ± 0.72 0.007
LDL chol. (mmol/L), Me [Q1; Q3] 3.10 [2.10; 3.50] 2.74 [1.76; 2.90] 0.03
HDL chol. (mmol/L), Me [Q1; Q3] 1.42 [1.17; 1.65] 1.11 [0.92; 1.21] 0.004
Triglycerides (mmol/L), Me [Q1; Q3] 1.21 [0.95; 1.98] 1.42 [0.92; 2.09] 0.99
hsCRP (mg/L), Me [Q1; Q3] 1.31 [0.80; 3.43] 4.47 [2.89; 7.32] <0.001
During the second test after 8.42± 1.38 days in 39 (65%) sub-
jects sinus rhythm was observed. There were no significant
differences between the treatments used in subgroups with
presence of sinus rhythm and AF persistence. Comparison of
both groups is presented in Table 1.
3.2. Initial OPG and TRAIL Concentration and Its Corre-
lations. The concentration of OPG during first visit (acute
onset of AF) was 5.94 [4.86; 8.08] pmol/L, at the control visit
6.40 [5.60; 7.09] pmol/L. The mean concentration of TRAIL
was 95.66 ± 34.62 pg/mL and 101.52 ± 32.27 pg/mL, respec-
tively. We found important statistical negative correlation
between OPG and TRAIL concentrations at first visit (𝑟 =
−0.54, 𝑝 < 0.001) and weaker but still important one at
the control visit (𝑟 = −0.35, 𝑝 = 0.02) (Figure 1). Impor-
tant differences between initial concentrations of analyzed
markers were observed in subgroups selected on the basis of
coronary artery disease (for both markers) and heart failure
(for OPG only) presence (Figure 2). The initial level of OPG
but not TRAIL correlated with age of patients (𝑟 = 0.44, 𝑝 <
0.001). We also found correlations between both markers’
initial levels and total cholesterol and hsCRP, with opposite
direction of mentioned correlations for OPG and TRAIL
(Figures 3 and 4). The TRAIL level correlated positively with
EF (𝑟 = 0.33; 𝑝 = 0.01) and negatively with left atrium
diameter (𝑟 = −0.28; 𝑝 = 0.03). The OPG concentration
was also higher in patients treated with acetylsalicylic acid
(ASA) (lnOPG: 1.97 ± 0.42 versus 1.76 ± 0.31 pmol/L;
𝑝 < 0.05), diuretics (2.06 ± 0.42 versus 1.75 ± 0.31 pmol/L;
𝑝 < 0.01), and insulin (1.84 ± 0.37 versus 2.39 ± 0.29 pmol/L;
𝑝 < 0.01). TRAIL level was higher in patients taking statins
(102.07 ± 33.92 versus 83.39 ± 32.33 pg/mL; 𝑝 < 0.05).
We have found no other differences in the concentrations
of the tested substances depending on the used treatment
(including oral antithrombotics). Then we compared initial
concentrations of OPG and TRAIL in subgroups selected on
the basis of CHA
2
DS
2
-VASc scoring. We found subsequent
increase of OPG but not the TRAIL in the model (Figure 5).
We also compare OPG level in patients with CHA
2
DS
2
-VASc
score <2 and ≥2 pkt. There was important difference in OPG
concentration between the subgroups (1.94 ± 0.38 versus
1.65 ± 0.29 pmol/L; 𝑝 < 0.01).
3.3. Return of Sinus Rhythm and Changes in Concentrations
of OPG and TRAIL. To evaluate the usefulness of examined
markers in predicting the effectiveness of pharmacological
cardioversion we compared initial concentrations of OPG
and TRAIL in subgroups with SR or AF in control visit.
There was no important difference in initial OPG and
TRAIL concentration between patients who later restore
sinus rhythmormaintainAF.Then, we assessed the dynamics
of changes in concentration of bothmarkers in two subgroups
separately and we observed important increase in TRAIL
concentration in subgroup with SR return (visit I versus visit
II: 94.11 ± 29.46 versus 111.39 ± 30.23 pg/mL; 𝑝 = 0.002)
and no significant changes in the group of AF maintenance
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Figure 1: Correlation between initial concentrations of OPG and
TRAIL.
(88.49 ± 40.65 versus 83.03 ± 28.25 pg/mL; NS). At the
control visit there was also important difference in the con-
centration of TRAIL between patients with sinus rhythm and
atrial fibrillation (111.39 ± 30.23 versus 83.03 ± 28.25 pg/mL;
𝑝 = 0.004).The level of OPG remained unchanged regardless
of the control rhythm (Figure 6).
4. Discussion
By assessing the circulating levels of OPG and TRAIL in
the patients with acute onset of AF and after pharmacolog-
ical cardioversion attempt we have demonstrated that the
markers present opposite interrelation. These findings could
be partially explained by opposite correlations of mentioned
markers with hsCRP and total cholesterol levels. Moreover,
the results may suggest generally beneficial effects of TRAIL
and unfavorable effects of OPG in the mentioned group,
as demonstrated particularly by correlation between OPG
level and CHA
2
DS
2
-VASc score and change in the concen-
tration of TRAIL in the successful cardioversion subgroup.
Although TRAIL and OPG were not useful in predicting the
effectiveness of pharmacological cardioversion, defined as the
presence of sinus rhythm within 7–10 days after the taking
treatment, TRAIL level increased after SR restoration while
OPG remained unchanged.
No particular restrictive inclusion criteria caused the
study group to reflect the complex spectrum of patients with
AF from patients with lone atrial fibrillation to the patients
with organic heart damage and numerous comorbidities.
Generally, although the sample characteristics were very
diverse, its demographic profile, comorbidity, and echocar-
diographic parameters did not differ considerably from data
from large registries for atrial fibrillation [21, 22]. Also, the
fact of pharmacological cardioversion choice as a treatment
corresponds to the practice of real life. Most studies of the
dynamics of biochemical markers in patients with acute AF
assess these markers change in demand on the effectiveness
of electrical cardioversion. However, pharmacological car-
dioversion is still themost commonmethodof restoring sinus
rhythm in clinical practice [23].
We have a very small amount of data concerning the
relationship between the AF and OPG/TRAIL system. The
first study which drew attention to the above problem was
Schnabel et al.’s work based on the population of the Fram-
ingham Offspring Study. Among the tested 12 inflammatory
markers only the OPG had significant prognostic value in
predicting the occurrence of AF [24]. In a study of Cao
et al., significantly higher expression of OPG in biopsy
material from right atrial appendagewas found inAF patients
compared to patients with sinus rhythm [17, 18]. However, we
have not identified in the available literature data concerning
the levels of serum OPG in patients with acute onset AF.
The mean concentration of TRAIL in the study group
was 95.66 ± 34.62 pg/mL. The literature on the relationship
between the concentration of TRAIL and AF is very limited.
In a small study (involving 25 participants) of Osmancik
et al. on patients undergoing ablation of AF they found a
mean concentration of the TRAIL 113.7 ± 29.4 pg/mL in
patients with paroxysmal AF and 116.9 ± 30.6 in subjects
with persistent AF [19]. The subjects, however, were younger
(59.5 ± 8.2 years) and coronary artery disease, significant
heart failure, and COPD were the exclusion criteria of the
study, which can explain a higher concentration of TRAIL
than observed in our study.
The results confirm a positive correlation of OPG and
negative correlation of TRAIL with cardiovascular risk fac-
tors. In the study we noted increasing with age levels of
OPG, higher levels of thismarker in subgroups with coronary
artery disease (CAD) and heart failure, and lower mean
concentration of the TRAIL in CAD. What is more OPG
concentration was higher in patients treated with ASA,
diuretics, and insulin, which can indirectly indicate a higher
concentration of the tested substance in patients with more
serious damage to the cardiovascular system. On the other
side higher levels of TRAIL in subgroup using statins suggest
beneficial influence of this drug class on the studied marker
system. A positive correlation between the concentration of
TRAIL and the EF and negative correlation with the size
of the left atrium were also established. With regard to the
above relations it is not surprising that we found a negative
correlation between serum concentrations of TRAIL and
OPG. Because OPG acts as a soluble receptor for TRAIL,
the interrelationships between these two substances merit
special attention.There is a hypothesis assuming that the fact
of the uptake and binding of TRAIL by OPG is a protective
mechanism against apoptosis [25]. Since OPG is released
from endothelial cells under the influence of the inflam-
matory cytokines, this hypothesis seems to be particularly
accurate with respect to the biology of endothelial cells.
However, there is also the opposite hypothesis put forward by
Secchiero et al., assuming originally favorable effect of TRAIL
depending on its anti-inflammatory and antiatherosclerotic
activity, inhibited by OPG as its decoy receptor [26]. Results
obtained by us seem to support this second hypothesis.
It is worth noting that our results relate to the soluble
form of TRAIL present in the blood serum. TRAIL bound
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Figure 2: Differences in OPG and TRAIL concentration concerning CAD and HF presence (1: present, 0: absent).
to the cell surface is characterized by a different biology, and
the example is the presence of TRAIL-expressing leukocytes
within the atherosclerotic lesions and positive relationship
between the degree of its expression and the atherosclerotic
plaque instability. It can explain the difference between the
results obtained by us and the results of Cao et al., who found
a positive correlation between the expression of the gene for
OPG and the presence of TRAIL transcript in tissue samples
taken from the left atrial appendage in patients with AF [17].
The thesis of the favorable impact of TRAIL in biology
AF appears to be confirmed in an established increase in the
concentration of this substance in patients who have expe-
rienced successful cardioversion. This observation remains
however in opposition to the results of Osmancik et al.,
which recorded decrease in the concentration of this marker
in patients undergoing successful ablation of AF at 3 and
6 months after surgery [19]. This fact was interpreted by
the authors of the publication as evidence of inhibition of
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Figure 3: Correlations between initial OPG concentration and hsCRP and total cholesterol.
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Figure 4: Correlations between initial TRAIL concentration and hsCRP and total cholesterol.
cardiomyocyte apoptosis and subsequent fibrosis of atria. As
TRAIL in vivo ismainly protective in relation to cardiovascu-
lar effects, this makes the above interpretation into question.
The discrepancy of our results with data from the cited study
beyond those concerning the examined groups differences
can be explained by the invasive nature of the intervention
and significantly longer duration of sinus rhythm at the time
of the assay.
The protective effect of TRAIL in patients with AF was
also proved by the results of Deftereos et al. [20]. These
researchers determined the concentration of this marker
in the blood collected at the time of catheterization of
the coronary sinus and the aorta. The difference of these
concentrations was presented as transcardial gradient of
TRAIL. The study was performed in patients within 7–9
days after successful electrical cardioversion of AF and the
results were related to the risk of AF recurrence within 6
months. Higher gradient of TRAIL indicating the increased
intracardiac production of thismarker proved to be a negative
predictor of arrhythmia recurrence.
Among the obtained data particularly noteworthy are
those demonstrating “reverse epidemiology” of total choles-
terol in the study group. Negative correlation with OPG and
positive correlation with TRAIL seem to be counterintuitive.
One of the possible explanations is opposite correlation
between total cholesterol and hsCRP.This finding underlines
the importance of inflammatory processes in biology of
AF even overcoming the classical connection between lipid
markers and cardiovascular risk [27].
This study is also the first assessing OPG in the context
of CHA
2
DS
2
-VASc calculation. Previous results concerning
OPG concentration in terms of issues related with the risk of
stroke regarded sinus rhythmpatients andwere contradictory
[28, 29]. Observed differences can be partly explained by the
relationship betweenOPG and the age of the respondents and
the presence of CAD and HF. On the other hand, it cannot
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Figure 6: Dynamics of OPG and TRAIL in SR and AF groups.
be excluded that the measurement of OPG concentration can
provide added value in the prediction of stroke in patients
with AF. Establishing this fact, however, is only possible in
eventual prospective studies.
5. Conclusions
The presented study supported the thesis that OPG
and TRAIL may contribute to pathogenesis of AF as,
respectively, negative and positive factor. Both markers
had been initially connected with the presence of common
risk factors but the return of sinus rhythm modulated their
balance. Although they were not useful in predicting the
return of sinus rhythm, it seems that they may reflect global
cardiovascular burden and correspond to thromboembolic
risk. Determining the suitability of OPG and TRAIL in
predicting complications of AF requires further prospective
studies.
8 BioMed Research International
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgment
The study was funded by the Department of Scientific
Research and Structural Funds, Jagiellonian University.
References
[1] J. Ball, M. J. Carrington, J. J. V.McMurray, and S. Stewart, “Atrial
fibrillation: profile and burden of an evolving epidemic in the
21st century,” International Journal of Cardiology, vol. 167, no. 5,
pp. 1807–1824, 2013.
[2] D. G. Wyse, A. L. Waldo, J. P. DiMarco et al., “A comparison
of rate control and rhythm control in patients with atrial
fibrillation,”The New England Journal of Medicine, vol. 347, no.
23, pp. 1825–1833, 2002.
[3] T. Watson, E. Shantsila, and G. Y. Lip, “Mechanisms of throm-
bogenesis in atrial fibrillation: Virchow’s triad revisited,” The
Lancet, vol. 373, no. 9658, pp. 155–166, 2009.
[4] M. Baud’huin, L.Duplomb, S. Teletchea et al., “Osteoprotegerin:
multiple partners for multiple functions,” Cytokine and Growth
Factor Reviews, vol. 24, no. 5, pp. 401–409, 2013.
[5] A. C. W. Zannettino, C. A. Holding, P. Diamond et al., “Osteo-
protegerin (OPG) is localized to the Weibel-Palade bodies of
human vascular endothelial cells and is physically associated
with von Willebrand factor,” Journal of Cellular Physiology, vol.
204, no. 2, pp. 714–723, 2005.
[6] B. J. Bennett, M. Scatena, E. A. Kirk et al., “Osteoprotegerin
inactivation accelerates advanced atherosclerotic lesion pro-
gression and calcification in older ApoE−/− mice,” Arterioscle-
rosis, Thrombosis, and Vascular Biology, vol. 26, no. 9, pp. 2117–
2124, 2006.
[7] F. Corallini, E. Rimondi, and P. Secchiero, “TRAIL and osteo-
protegerin: a role in endothelial physiopathology?” Frontiers in
Bioscience, vol. 13, no. 1, pp. 135–147, 2008.
[8] M. Abedin, T. Omland, T. Ueland et al., “Relation of osteopro-
tegerin to coronary calcium and aortic plaque (from the Dallas
Heart Study),” The American Journal of Cardiology, vol. 99, no.
4, pp. 513–518, 2007.
[9] S. Jono, Y. Ikari, A. Shioi et al., “Serum osteoprotegerin levels
are associated with the presence and severity of coronary artery
disease,” Circulation, vol. 106, no. 10, pp. 1192–1194, 2002.
[10] S. Kiechl, G. Schett, G. Wenning et al., “Osteoprotegerin is a
risk factor for progressive atherosclerosis and cardiovascular
disease,” Circulation, vol. 109, no. 18, pp. 2175–2180, 2004.
[11] T. Omland, T. Ueland, A. M. Jansson et al., “Circulating
osteoprotegerin levels and long-term prognosis in patients with
acute coronary syndromes,” Journal of the American College of
Cardiology, vol. 51, no. 6, pp. 627–633, 2008.
[12] R. Mogelvang, S. H. Pedersen, A. Flyvbjerg et al., “Comparison
of osteoprotegerin to traditional atherosclerotic risk factors and
high-sensitivity c-reactive protein for diagnosis of atheroscle-
rosis,” The American Journal of Cardiology, vol. 109, no. 4, pp.
515–520, 2012.
[13] A. M. Bla´zquez-Medela, L. Garc´ıa-Ortiz, M. A. Go´mez-Marcos
et al., “Osteoprotegerin is associated with cardiovascular risk
in hypertension and/or diabetes,” European Journal of Clinical
Investigation, vol. 42, no. 5, pp. 548–556, 2012.
[14] E. Stępien´, D. Fedak, P. Klimeczek et al., “Osteoprotegerin, but
not osteopontin, as a potential predictor of vascular calcification
in normotensive subjects,”Hypertension Research, vol. 35, no. 5,
pp. 531–538, 2012.
[15] G. Zauli, A. Pandolfi, A. Gonelli et al., “Tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) sequentially up-
regulates nitric oxide and prostanoid production in primary
human endothelial cells,”Circulation Research, vol. 92, no. 7, pp.
732–740, 2003.
[16] S. Volpato, L. Ferrucci, P. Secchiero et al., “Association of tumor
necrosis factor-related apoptosis-inducing ligand with total and
cardiovascular mortality in older adults,” Atherosclerosis, vol.
215, no. 2, pp. 452–458, 2011.
[17] H. Cao, J. Wang, L. Xi, O. D. Røe, Y. Chen, and D. Wang, “Dys-
regulated atrial gene expression of osteoprotegerin/receptor
activator of nuclear factor-𝜅B (RANK)/RANK ligand axis in the
development and progression of atrial fibrillation,” Circulation
Journal, vol. 75, no. 12, pp. 2781–2788, 2011.
[18] H. Cao, Q. Li, M. Li et al., “Osteoprotegerin/RANK/RANKL
axis and atrial remodeling in mitral valvular patients with atrial
fibrillation,” International Journal of Cardiology, vol. 166, no. 3,
pp. 702–708, 2013.
[19] P. Osmancik, Z. Peroutka, P. Budera et al., “Decreased apoptosis
following successful ablation of atrial fibrillation,” Cardiology,
vol. 116, no. 4, pp. 302–307, 2010.
[20] S.Deftereos,G.Giannopoulos, C.Kossyvakis et al., “Association
of post-cardioversion transcardiac concentration gradient of
soluble tumor necrosis factor-related apoptosis-inducing ligand
(sTRAIL) and inflammatory biomarkers to atrial fibrillation
recurrence,”Clinical Biochemistry, vol. 46, no. 12, pp. 1020–1025,
2013.
[21] R. Nieuwlaat, A. Capucci, A. J. Camm et al., “Atrial fibrillation
management: a prospective survey in ESC member countries:
the Euro Heart Survey on Atrial Fibrillation,” European Heart
Journal, vol. 26, no. 22, pp. 2422–2434, 2005.
[22] M. Alam, S. J. Bandeali, S. A. Shahzad, and N. Lakkis, “Real-
life global survey evaluating patients with atrial fibrillation
(REALISE-AF): results of an international observational reg-
istry,” Expert Review of Cardiovascular Therapy, vol. 10, no. 3,
pp. 283–291, 2012.
[23] R. Pisters, R. Nieuwlaat, M. H. Prins et al., “Clinical correlates
of immediate success and outcome at 1-year follow-up of real-
world cardioversion of atrial fibrillation: the EuroHeart Survey,”
Europace, vol. 14, no. 5, pp. 666–674, 2012.
[24] R. B. Schnabel, M. G. Larson, J. F. Yamamoto et al., “Relation
of multiple inflammatory biomarkers to incident atrial fibrilla-
tion,”TheAmerican Journal of Cardiology, vol. 104, no. 1, pp. 92–
96, 2009.
[25] L. B. Pritzker, M. Scatena, and C. M. Giachelli, “The role of
osteoprotegerin and tumor necrosis factor-related apoptosis-
inducing ligand in human microvascular endothelial cell sur-
vival,”Molecular Biology of the Cell, vol. 15, no. 6, pp. 2834–2841,
2004.
[26] P. Secchiero, F. Corallini, A. P. Beltrami et al., “An imbalanced
OPG/TRAIL ratio is associated to severe acute myocardial
infarction,” Atherosclerosis, vol. 210, no. 1, pp. 274–277, 2010.
[27] N. Wu, B. Xu, Y. Xiang et al., “Association of inflammatory
factors with occurrence and recurrence of atrial fibrillation: a
meta-analysis,” International Journal of Cardiology, vol. 169, no.
1, pp. 62–72, 2013.
BioMed Research International 9
[28] M. Nybo, S. P. Johnsen, C. Dethlefsen et al., “Lack of observed
association between high plasma osteoprotegerin concentra-
tions and ischemic stroke risk in a healthy population,” Clinical
Chemistry, vol. 54, no. 12, pp. 1969–1974, 2008.
[29] R.Mogelvang, S. Haahr-Pedersen, M. Bjerre et al., “Osteoprote-
gerin improves risk detection by traditional cardiovascular risk
factors and hsCRP,” Heart, vol. 99, no. 2, pp. 106–110, 2013.
